ArticleJournal of neuropsychology2026
Frontal Assessment Battery: Reliability, validity and discriminative ability in a Spanish sample of amnestic mild cognitive impairment and Alzheimer's disease.
Article in Journal of neuropsychology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Dementia constitutes one of the most widespread neurological disorders, representing an important health concern due to its increasing prevalence. Among the various types of dementia, Alzheimer's disease (AD) is the most common in the elderly, characterized by episodic memory impairment and also a decline in executive functions. Mild cognitive impairment (MCI) is considered a transitional stage between normal ageing and dementia, often described as a pre-dementia state. Distinguishing between these states is of paramount importance for the detection and appropriate care of patients. Functional Assessment Battery (FAB) is a screening tool for assessing executive function. In this study, 36 healthy individuals (HC), 31 single-domain amnestic mild cognitive impairment (aMCI) patients, and 29 Alzheimer's disease (AD) patients were assessed using FAB to determine its reliability, validity, and discriminative validity in a Spanish sample. Results indicated a good internal consistency of FAB in the AD sample (α = .71), but not in the aMCI group (α = .49). Significant differences between HC and both aMCI and AD groups were observed in the total scores of FAB. The FAB also showed good accuracy in distinguishing between HC and patients (AUC = 0.85), with an estimated optimal cut-off point of 16.5. However, its ability to distinguish between aMCI and AD individuals was lower (AUC = 0.68). More studies are necessary to corroborate our results using larger samples.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.